TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00764439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy
Description: Nicotine replacement therapy with Standard NRT user direction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Description: Nicotine replacement therapy with a Novel NRT user direction
Study: NCT03075618

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires
Study: NCT03367390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
Study: NCT02575001

Intervention type: BEHAVIORAL
Intervention: Psychological background determinations
Description: For the psychological background determinations a structured interview and questionnaires will be administered:~1. Child Attachment Interview (CAI)~2. General/sociodemographic questionnaire with the questions on diabetes management, current health status and the child's development in the infancy~3. Parenting Stress Index with the 19-item Life Stress Scale (PSI)~4. Achenbach System of Empirically Based Assessment (CBCL, YSR)~5. Holmes and Rahe Social readjustment rating scale~6. Lifetime Incidence of Traumatic Events (LITE) - parent and child reports of child's trauma/loss history (LITE- S/ P)~7. Experiences in Close Relationships - Relationship Structures questionnaire (ECR-RS)

Intervention type: BEHAVIORAL
Intervention: Psychological background determinations
Description: For the psychological background determinations a structured interview and questionnaires will be administered:~1. Child Attachment Interview (CAI)~2. General/sociodemographic questionnaire with the questions on diabetes management, current health status and the child's development in the infancy~3. Parenting Stress Index with the 19-item Life Stress Scale (PSI)~4. Achenbach System of Empirically Based Assessment (CBCL, YSR)~5. Holmes and Rahe Social readjustment rating scale~6. Lifetime Incidence of Traumatic Events (LITE) - parent and child reports of child's trauma/loss history (LITE- S/ P)~7. Experiences in Close Relationships - Relationship Structures questionnaire (ECR-RS)

Intervention type: GENETIC
Intervention: Genetic susceptibility determination
Description: DNA will be isolated from the patients' blood samples and form the control subjects buccal swabs. The genes with expected influence to stress reactivity and mental disorders will be tested.

Intervention type: GENETIC
Intervention: Genetic susceptibility determination
Description: DNA will be isolated from the patients' blood samples and form the control subjects buccal swabs. The genes with expected influence to stress reactivity and mental disorders will be tested.

Intervention type: PROCEDURE
Intervention: Cortisol release test
Description: Synacthen test - will be used with the group of patients with type 1 diabetes to measure HPA axis reactivity

Intervention type: PROCEDURE
Intervention: Saliva cortisol measurement
Description: Saliva cortisol measurement - will be used with the patients before and after the Synacthen test and with the Hashimoto thyroiditis and the healthy control group before and after the Child Attachment Interview

Intervention type: PROCEDURE
Intervention: Saliva cortisol measurement
Description: Saliva cortisol measurement - will be used with the patients before and after the Synacthen test and with the Hashimoto thyroiditis and the healthy control group before and after the Child Attachment Interview
Study: NCT02076438

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: Randomized to receive probiotics or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Randomized to receive probiotics or placebo
Study: NCT00598273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: As prescribed, starting dose of 0.75 microgram per kilogram (mcg/kg) administered by subcutaneous injection once every 2 weeks. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
Study: NCT03776227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01146782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attune Sleep Apnea System
Description: Console and mouthpiece sleep apnea system
Study: NCT03623373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered at a dose of 90 mg/m\^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: In Cycle 1, rituximab will be administered at a dose of 375 mg/m\^2 IV on Day 1 or 2 at the investigator's discretion in order to reduce the risk of a first infusion reaction. Rituximab will be given on Day 1 of Cycles 1 through 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: The capsules should be swallowed intact with water and with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: On Days 1 and 2 of Cycles 4-6, following rituximab dosing, cytarabine will be administered IV every 12 hours for a total of 4 doses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Until collection of ≥ 2 x 106 CD34+ stem cells / kg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: -Baseline, end of Cycle 3, 4-6 weeks after Cycle 6 Day 1, and if the patient discontinues protocol therapy prior to completion of Cycle 6

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral rinse
Description: -Baseline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow collection
Description: -Bone marrow will be collected at baseline if the patient requires a marrow for staging purposes and at end of treatment if the patient requires a marrow for restaging.
Study: NCT04173351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Counseling
Description: Following the pretests between the 28th and the 34th gestational weeks, nulliparous women in the intervention group received a presentation on childbirth preparation at a room of the obstetrics clinic. The education was completed in two sections in a single day. Each session took about 45 minutes there was a 15-minute break between the sessions. Following the education, the questions of the participants were responded and educational brochures on childbirth preparation were given to the participants. One of the researchers of this study telephoned the participant women in the intervention group one week after the childbirth education and provided counseling service about the demands and the points that the nulliparous women wondered.
Study: NCT01605916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Tablet Oral bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Tablet Oral bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Tablet Oral bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Tablet Oral bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Tablet Oral bid
Study: NCT03301129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke
Description: See arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke
Description: See arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke
Description: See arm/group descriptions.
Study: NCT03594201

Intervention type: OTHER
Intervention: semen pretreatment
Description: semen pretreatment

Intervention type: OTHER
Intervention: semen pretreatment
Description: semen pretreatment

Intervention type: OTHER
Intervention: semen pretreatment
Description: semen pretreatment

Intervention type: OTHER
Intervention: semen pretreatment
Description: semen pretreatment
Study: NCT03743454

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be applied.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be applied.
Study: NCT02374684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methosulide
Description: Tolerability Study:~Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg~,group 2:depending on the adverse drug reaction,150mg/250mg)~Food Effect on the Pharmacokinetics:~single dose(100mg),two status(Feeding and fasting), washout period(7 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match with experimental groups
Study: NCT04445142

Intervention type: PROCEDURE
Intervention: fovea-sparing internal limiting membrane peeling
Description: fovea-sparing internal limiting membrane peeling surgery
Study: NCT00879385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacogen™ (decitabine)
Description: Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).~Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vectibix® (panitumumab)
Description: Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival.~DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.~Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr
Study: NCT01338337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
Study: NCT01344915

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locked knee brace

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locked knee brace
Study: NCT04107714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STC
Description: The peer-led and web-based group program contains four lessons plus one booster session:~* Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weight their pros and cons of (non-)disclosing their child's mental illness.~* Lesson 2: Different ways to disclose: Participants learn about different ways to disclose and their respective pros and cons. Afterwards participants discuss possible responses they might experience and develop strategies to cope with.~* Lesson 3: Communication about disclosure between parents and their child: Participants discuss pros and cons of (non-)disclosure for their children and how to negotiate whether to disclose or not.~* Lesson 4: Telling your story: Participants learn how to tell their own story.~* In a booster session, participants discuss their experiences with disclosure or non-disclosure.
Study: NCT01046565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene cream 0.1%
Description: adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene lotion 0.1%
Description: adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
Study: NCT00148759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: LPV/r 800/200 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV/r
Description: LPV/r 800/200 mg once daily
Study: NCT02851303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine wean protocol as described in arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone wean protocol as described in arm description
Study: NCT04064658

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic preconditioning
Description: Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Encephaloduroarteriosynangiosis
Description: Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Encephaloduroarteriosynangiosis
Description: Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease
Study: NCT03546621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B
Description: 2 mg, once daily, subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex-B
Description: 5 mg, once daily, subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex-B
Description: 10 mg, once daily, subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg
Study: NCT02313701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized visual presentation
Description: Visual presentations will address what type of procedure they will undergo, the risks and benefits of the procedure (i.e. injury to nearby organs, risks of infection and bleeding, risk of re-operation), alternative treatments to the procedure, what to expect during the pre-operative period, and what to expect in the post-operative period (i.e. urinary catheter, constipation, pain management, hospital stay).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized visual presentation
Description: Visual presentations will address what type of procedure they will undergo, the risks and benefits of the procedure (i.e. injury to nearby organs, risks of infection and bleeding, risk of re-operation), alternative treatments to the procedure, what to expect during the pre-operative period, and what to expect in the post-operative period (i.e. urinary catheter, constipation, pain management, hospital stay).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized visual presentation
Description: Visual presentations will address what type of procedure they will undergo, the risks and benefits of the procedure (i.e. injury to nearby organs, risks of infection and bleeding, risk of re-operation), alternative treatments to the procedure, what to expect during the pre-operative period, and what to expect in the post-operative period (i.e. urinary catheter, constipation, pain management, hospital stay).
Study: NCT00646646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: sedative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Sedative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: sedative

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: saline placebo
Study: NCT03776695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tyzivumab
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tyzivumab
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tyzivumab
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tyzivumab
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline
Study: NCT01984073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ER Niacin Oral Fat Challenge
Description: Extended release niacin 2000 mg at hour 0, followed by oral fat challenge at hour 1.
Study: NCT03776695

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline
Study: NCT01984073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR Niacin Oral Fat Challenge
Description: Nialor(R) 500mg or Placebo at hour 0, 2, 4, and 6. Oral fat challenge at hour 1 (one hour after first dose of immediate-release niacin)
Study: NCT03074565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic alone
Description: Sanative therapy using ultrasonic instrumentation alone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic+
Description: Sanative therapy using ultrasonic plus hand instrumentation
Study: NCT00226590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Induction Chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation Therapy will begin on day 57 if there has been adequate hematologic recovery from Induction Chemotherapy.
Study: NCT02394314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study: NCT04143685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Oral administration of cytotec every 4 hours until a maximum of 6 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intravenous infusion of Pitocin through an IVAC until delivery
Study: NCT01207375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: memory retraining exercises
Description: Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo control memory exercises
Description: Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 placebo control sessions.
Study: NCT01111708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Close Rectal Dissection - IPAA
Description: Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Close Rectal Dissection - IPAA
Description: Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Close Rectal Dissection - IPAA
Description: Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis
Study: NCT03782519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysis frequency reduction
Description: At initiation, frequency of dialysis will be reduced to 2 weekly sessions (incremental HD)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frailty diagnosis
Description: Before randomization, we will determine whether patients are frail. We will define frailty as the presence of at least three of the following five conditions: malnourished according to dietitian assessment and/or short form of Mini Nutritional Assessment (MNA), grip strength and gait speed using participants' scores on the SF-36 Physical Functioning (PF) scale, exhaustion using in the quality of life questionnaire SF-36 vitality (VT) scale and physical activity according to patient assessment (one single question)
Study: NCT01984073

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Fat Challenge
Description: Placebo at hour 0. Oral fat challenge at hour 1, followed by placebo at hours 2,4,and 6